Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Income towards Parent Company (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Income towards Parent Company data on record, last reported at -$9.8 million in Q3 2025.

  • For Q3 2025, Income towards Parent Company rose 75.13% year-over-year to -$9.8 million; the TTM value through Sep 2025 reached -$1.7 million, up 96.88%, while the annual FY2023 figure was -$23.4 million, 28.12% up from the prior year.
  • Income towards Parent Company reached -$9.8 million in Q3 2025 per CRVS's latest filing, down from -$7.6 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $15.7 million in Q1 2025 and bottomed at -$39.5 million in Q3 2024.
  • Average Income towards Parent Company over 4 years is -$7.5 million, with a median of -$6.0 million recorded in 2023.
  • Peak YoY movement for Income towards Parent Company: tumbled 669.91% in 2024, then surged 364.98% in 2025.
  • A 4-year view of Income towards Parent Company shows it stood at -$5.7 million in 2022, then grew by 0.26% to -$5.7 million in 2023, then tumbled by 599.61% to -$39.5 million in 2024, then soared by 75.13% to -$9.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Income towards Parent Company were -$9.8 million in Q3 2025, -$7.6 million in Q2 2025, and $15.7 million in Q1 2025.